. . "Insulin is still considered to be the most effective treatment in type 2 diabetes mellitus (T2DM) patients. However, concerns still remain about gaining weight in association to insulin therapy. In our retrospective survey of 189 patients (105 women and 84 men) with T2DM who were commenced on insulin therapy for poor diabetes control, we looked at the development of their weight and glycated haemoglobin in the first years after switching to insulin. The mean age at diabetes diagnosis in our cohort was 50.7 years and the mean time from manifest diabetes to initiation of insulin therapy was 9.7 years. The patients increased their weight from 85.53 kg at initiation of insulin therapy to 88.90 after four years, but failed to reach the maximum weight they had had before detecting diabetes (91.78) and approached their weight at T2DM diagnosis (87.98). The higher the patients weight/BMI prior to diabetes, the greater was the weight loss prior to administering insulin, and the longer the time period between manifest diabetes and initiation of insulin therapy, the higher was the decrease in BMI."@en . "Studie MOTUDI \u2013 ovlivn\u011Bn\u00ED hmotnosti inzulinovou l\u00E9\u010Dbou u nemocn\u00FDch s DM2 v \u010CR" . . "1" . "Klinick\u00E1 farmakologie a farmacie" . "MOTUDI study \u2013 influencing weight with insulin therapy in type 2 diabetes patients in the Czech Republic"@en . . "[1654FC3C1711]" . . "RIV/00064203:_____/12:8598!RIV13-MZ0-00064203" . . . . "RIV/00064203:_____/12:8598" . "Studie MOTUDI \u2013 ovlivn\u011Bn\u00ED hmotnosti inzulinovou l\u00E9\u010Dbou u nemocn\u00FDch s DM2 v \u010CR"@cs . . . "I" . "26" . . . "Inzulin je st\u00E1le pova\u017Eov\u00E1n za nejefektivn\u011Bj\u0161\u00ED l\u00E9\u010Dbu nemocn\u00FDch s DM2, ale tak\u00E9 p\u0159etrv\u00E1v\u00E1 obava ze zvy\u0161ov\u00E1n\u00ED hmotnosti v souvislosti s inzulinovou l\u00E9\u010Dbou. V na\u0161em retrospektivn\u00EDm sledov\u00E1n\u00ED 189 nemocn\u00FDch (105 \u017Een a 84 mu\u017E\u016F) s DM2, kter\u00FDm byla zah\u00E1jena inzulinov\u00E1 l\u00E9\u010Dba pro neuspokojivou kompenzaci diabetu, jsme sledovaly v\u00FDvoj jejich hmotnosti a glykovan\u00E9ho hemoglobinu v prvn\u00EDch letech po zm\u011Bn\u011B l\u00E9\u010Dby na inzulin. Pr\u016Fm\u011Brn\u00FD v\u011Bk p\u0159i odhalen\u00ED diabetu byl v na\u0161em souboru 50,7 roku a pr\u016Fm\u011Brn\u00E1 doba mezi manifestac\u00ED cukrovky a zah\u00E1jen\u00EDm inzulinov\u00E9 l\u00E9\u010Dby byla 9,7 let. Nemocn\u00ED zv\u00FD\u0161ili svoji hmotnost z 85,53 kg p\u0159i zah\u00E1jen\u00ED inzulinov\u00E9 l\u00E9\u010Dby na 88,90 po 4 letech, ale nedos\u00E1hli sv\u00E9 maxim\u00E1ln\u00ED hmotnosti, kterou m\u011Bli p\u0159ed odhalen\u00EDm diabetu (91,78) a p\u0159ibl\u00ED\u017Eili se hmotnosti p\u0159i odhalen\u00ED DM2 (87,98). \u010C\u00EDm vy\u0161\u0161\u00ED byla hmotnost/BMI nemocn\u00E9ho p\u0159ed diabetem, t\u00EDm v\u011Bt\u0161\u00ED byl \u00FAbytek hmotnosti p\u0159ed pod\u00E1n\u00EDm inzulinu, a \u010D\u00EDm del\u0161\u00ED byla doba mezi manifestac\u00ED diabetu a zah\u00E1jen\u00EDm inzulinov\u00E9 l\u00E9\u010Dby, t\u00EDm byl vy\u0161\u0161\u00ED pokles BMI." . "Studie MOTUDI \u2013 ovlivn\u011Bn\u00ED hmotnosti inzulinovou l\u00E9\u010Dbou u nemocn\u00FDch s DM2 v \u010CR" . "Inzulin je st\u00E1le pova\u017Eov\u00E1n za nejefektivn\u011Bj\u0161\u00ED l\u00E9\u010Dbu nemocn\u00FDch s DM2, ale tak\u00E9 p\u0159etrv\u00E1v\u00E1 obava ze zvy\u0161ov\u00E1n\u00ED hmotnosti v souvislosti s inzulinovou l\u00E9\u010Dbou. V na\u0161em retrospektivn\u00EDm sledov\u00E1n\u00ED 189 nemocn\u00FDch (105 \u017Een a 84 mu\u017E\u016F) s DM2, kter\u00FDm byla zah\u00E1jena inzulinov\u00E1 l\u00E9\u010Dba pro neuspokojivou kompenzaci diabetu, jsme sledovaly v\u00FDvoj jejich hmotnosti a glykovan\u00E9ho hemoglobinu v prvn\u00EDch letech po zm\u011Bn\u011B l\u00E9\u010Dby na inzulin. Pr\u016Fm\u011Brn\u00FD v\u011Bk p\u0159i odhalen\u00ED diabetu byl v na\u0161em souboru 50,7 roku a pr\u016Fm\u011Brn\u00E1 doba mezi manifestac\u00ED cukrovky a zah\u00E1jen\u00EDm inzulinov\u00E9 l\u00E9\u010Dby byla 9,7 let. Nemocn\u00ED zv\u00FD\u0161ili svoji hmotnost z 85,53 kg p\u0159i zah\u00E1jen\u00ED inzulinov\u00E9 l\u00E9\u010Dby na 88,90 po 4 letech, ale nedos\u00E1hli sv\u00E9 maxim\u00E1ln\u00ED hmotnosti, kterou m\u011Bli p\u0159ed odhalen\u00EDm diabetu (91,78) a p\u0159ibl\u00ED\u017Eili se hmotnosti p\u0159i odhalen\u00ED DM2 (87,98). \u010C\u00EDm vy\u0161\u0161\u00ED byla hmotnost/BMI nemocn\u00E9ho p\u0159ed diabetem, t\u00EDm v\u011Bt\u0161\u00ED byl \u00FAbytek hmotnosti p\u0159ed pod\u00E1n\u00EDm inzulinu, a \u010D\u00EDm del\u0161\u00ED byla doba mezi manifestac\u00ED diabetu a zah\u00E1jen\u00EDm inzulinov\u00E9 l\u00E9\u010Dby, t\u00EDm byl vy\u0161\u0161\u00ED pokles BMI."@cs . "171991" . "insulin therapy; weight"@en . "5"^^ . . "MOTUDI study \u2013 influencing weight with insulin therapy in type 2 diabetes patients in the Czech Republic"@en . "Peru\u0161i\u010Dov\u00E1, Jind\u0159i\u0161ka" . . "1"^^ . "1212-7973" . "1"^^ . "CZ - \u010Cesk\u00E1 republika" . "http://www.klinickafarmakologie.cz/pdfs/far/2012/01/09.pdf" . "Studie MOTUDI \u2013 ovlivn\u011Bn\u00ED hmotnosti inzulinovou l\u00E9\u010Dbou u nemocn\u00FDch s DM2 v \u010CR"@cs .